Scientific Sessions

  • Home
  • Program
  • Scientific Sessions

Advances in pharmaceutics and drug formulation are revolutionizing the way therapeutic agents are delivered, enhancing drug efficacy, safety, and patient compliance. Recent developments include the design of targeted drug delivery systems such as nanoparticles, liposomes, and dendrimers, which enable precise delivery of drugs to specific tissues or cells, minimizing side effects. Innovations in controlled and sustained release formulations ensure a steady therapeutic effect over time, reducing dosing frequency.

Nanotechnology-based drug delivery is a rapidly advancing field that utilizes nanoscale materials—typically ranging from 1 to 100 nanometers—for the targeted delivery of therapeutic agents. This approach aims to overcome the limitations of conventional drug delivery methods by enhancing drug solubility, improving bioavailability, enabling controlled release, and minimizing side effects.

The major advantages of nanotechnology-based drug delivery include reduced dosage frequency, enhanced therapeutic efficacy, lower systemic toxicity, and the ability to cross biological barriers like the blood-brain barrier. As research continues to progress, this technology holds immense promise for personalized medicine and the treatment of previously hard-to-treat diseases.

Targeted drug delivery systems (TDDS) are advanced therapeutic strategies designed to deliver drugs specifically to diseased tissues or cells, minimizing systemic exposure and side effects. Unlike conventional drug delivery, which disperses medication throughout the body, TDDS aim to increase the concentration of the drug at the intended site of action.

These systems utilize carriers such as nanoparticles, liposomes, dendrimers, or conjugated molecules that can recognize and bind to specific biological markers, often overexpressed on diseased cells, such as cancer cells. Targeting mechanisms include passive targeting (relying on biological factors like enhanced permeability and retention in tumors) and active targeting (using ligands like antibodies or peptides that bind selectively to receptors on target cells).

Transdermal drug delivery involves administering medications through the skin for systemic effects. Drugs are absorbed through the skin layers and into the bloodstream. This route bypasses the gastrointestinal tract and first-pass metabolism, improving bioavailability. Transdermal patches are the most common form, offering controlled and sustained drug release. It is ideal for drugs with low molecular weight and good lipophilicity. Challenges include limited permeability for certain drugs and potential for skin irritation.


Biodegradable and Stimuli-Responsive Carriers are advanced drug delivery systems designed to enhance therapeutic efficacy while minimizing side effects. These carriers play a crucial role in modern pharmaceutics, particularly in targeted and controlled drug release.

Biodegradable carriers are made from materials that naturally degrade into non-toxic byproducts within the body. Common biodegradable materials include poly(lactic acid) (PLA), poly(glycolic acid) (PGA), poly(lactic-co-glycolic acid) (PLGA), and natural polymers like chitosan and gelatin. These carriers ensure sustained drug release over time and eliminate the need for surgical removal after delivering the therapeutic agent.

Stimuli-responsive carriers, also known as smart carriers, release drugs in response to specific internal or external triggers. These triggers include pH changes, temperature shifts, enzymatic activity, redox conditions, or external stimuli like light, ultrasound, or magnetic fields. This approach allows for site-specific and time-controlled drug release, improving targeting and reducing systemic toxicity.

Controlled and Sustained Release Formulations: A Brief
Controlled and sustained release formulations are advanced drug delivery systems designed to release therapeutic agents at a predetermined rate, duration, and location, ensuring optimal drug concentration in the bloodstream or target tissues over an extended period.

Sustained Release (SR) systems aim to maintain a steady drug level by slowly releasing the drug over time, reducing the frequency of dosing and improving patient compliance. 

Controlled Release (CR) formulations offer more precise control over drug release patterns, often incorporating mechanisms that respond to environmental stimuli (e.g., pH, temperature) or biological triggers. 

Personalized medicine is a transformative approach to healthcare that tailors medical treatment to the individual characteristics of each patient, such as genetic makeup, lifestyle, and environment. It moves away from the traditional "one-size-fits-all" model by using biomarkers, genomics, and diagnostic tools to predict disease risk, treatment response, and optimal drug dosage.

Precision drug delivery is an integral component of personalized medicine. It involves designing drug delivery systems that target specific cells, tissues, or disease sites, thereby enhancing therapeutic efficacy and minimizing side effects. Technologies like nanoparticle carriers, implantable devices, and ligand-receptor targeting are commonly employed to achieve this specificity.

Biopharmaceutics is the branch of pharmaceutical science that studies the relationship between the physical and chemical properties of a drug, the dosage form in which it is given, and the route of administration on the rate and extent of its absorption. It plays a critical role in drug development and formulation, ensuring optimal drug efficacy and safety. Key considerations include solubility, permeability, stability, and how formulation factors influence the bioavailability of the drug.

Pharmacokinetics involves the study of the time course of drug absorption, distribution, metabolism, and excretion (ADME) in the body. It quantitatively analyzes how a drug moves through the body, determining factors like half-life, clearance, volume of distribution, and bioavailability. Pharmacokinetics is essential for designing dosing regimens and understanding drug interactions.

3D printing, also known as additive manufacturing, is revolutionizing pharmaceutical drug delivery by enabling the precise fabrication of personalized dosage forms with complex geometries and controlled release profiles. This technology builds drug formulations layer by layer using computer-aided design (CAD), offering unparalleled customization and flexibility.

Key Advantages:
  • Personalized Medicine: 3D printing allows tailoring of dosage strength, shape, and drug combinations based on individual patient needs, improving treatment efficacy and adherence.
  • Complex Drug Release Profiles: It supports fabrication of multi-layered or compartmentalized tablets for immediate, delayed, or sustained release in a single unit.
  • On-Demand Manufacturing: Enables point-of-care drug production in hospitals or pharmacies, reducing the need for large-scale inventory and improving drug accessibility.
  • Improved Bioavailability: Custom geometries and porosities can enhance dissolution rates and drug absorption, particularly for poorly soluble drugs.

mRNA and nucleic acid delivery systems represent a cutting-edge area in modern therapeutics, enabling the use of genetic material—such as messenger RNA (mRNA), small interfering RNA (siRNA), and DNA—for the treatment and prevention of various diseases. These systems are essential for delivering fragile and negatively charged nucleic acids into target cells while protecting them from degradation by nucleases in the body.
mRNA delivery gained global attention through mRNA-based COVID-19 vaccines, which demonstrated its potential for rapid and scalable vaccine development. However, mRNA and other nucleic acids face challenges like instability, immune activation, and inefficient cellular uptake, necessitating the use of delivery vehicles.

Key delivery systems include:
  • Lipid nanoparticles (LNPs): Most widely used carriers, especially in mRNA vaccines, due to their ability to encapsulate and protect nucleic acids and facilitate endosomal escape.
  • Polymeric nanoparticles: Made from biodegradable polymers such as PLGA or chitosan, offering controlled release and biocompatibility.
  • Viral vectors: Highly efficient but can have safety concerns like immunogenicity and insertional mutagenesis.
  • Peptide-based carriers and dendrimers: Provide targeted and efficient delivery with lower toxicity profiles.
  • Exosomes and extracellular vesicles: Natural carriers showing promise in delivering RNA with minimal immunogenicity.

Artificial Intelligence (AI) is revolutionizing drug design and delivery by accelerating drug discovery, improving precision, and optimizing therapeutic outcomes. AI techniques such as machine learning (ML), deep learning, and neural networks are increasingly used to analyze vast datasets, predict drug-target interactions, identify potential drug candidates, and optimize molecular structures with high efficiency.

In drug design, AI facilitates virtual screening, de novo drug design, and lead optimization by predicting molecular properties, binding affinities, and pharmacokinetic parameters. This significantly reduces the time and cost associated with traditional trial-and-error methods.


Clinical Trials are systematic studies conducted to evaluate the safety, efficacy, and optimal use of new drugs, biologics, or medical devices in human subjects. They are typically divided into four phases:
  • Phase I focuses on safety and dosage in a small group of healthy volunteers.
  • Phase II evaluates efficacy and side effects in a larger patient population.
  • Phase III confirms effectiveness, monitors side effects, and compares the drug to standard treatments in large populations.
  • Phase IV occurs post-approval and gathers real-world data on long-term effectiveness and safety.

Translational Pharmaceutics bridges the gap between drug discovery and clinical application. It integrates formulation development, real-time adaptive manufacturing, and clinical testing in a seamless workflow. This approach accelerates the transition from lab-based research to human trials by allowing formulation optimization and clinical assessment to occur concurrently.

Pharmaceutical packaging innovations play a crucial role in ensuring drug stability, patient safety, compliance, and supply chain efficiency. Recent advancements in this area focus on smart, sustainable, and patient-centric solutions.

Sustainable packaging is gaining momentum, with companies adopting biodegradable, recyclable, and compostable materials to reduce environmental impact. Innovations include plant-based plastics, paper-based blister packs, and reduced secondary packaging.

Child-resistant and senior-friendly designs enhance safety and accessibility. Features such as easy-to-open closures, tactile indicators, and color-coded systems support diverse patient needs.

Active and intelligent packaging—which includes desiccants, oxygen scavengers, and temperature-sensitive indicators—ensures the stability of sensitive pharmaceuticals, especially biologics and injectables.
Overall, pharmaceutical packaging innovations are reshaping the industry by combining functionality, sustainability, and digital technology to improve drug delivery, patient outcomes, and regulatory compliance.

The commercialization of Novel Drug Delivery Systems (NDDS) has gained significant momentum due to increasing demand for targeted, efficient, and patient-friendly therapies. NDDS technologies, including liposomes, nanoparticles, transdermal patches, and sustained-release formulations, are being widely adopted to enhance therapeutic outcomes and improve drug bioavailability.

Pharmaceutical nanocarriers are advanced drug delivery systems designed to enhance the efficacy and specificity of cancer therapies while minimizing systemic toxicity. These nanoscale carriers, typically ranging from 1 to 1000 nanometers in size, enable the targeted delivery of chemotherapeutic agents directly to tumor sites through passive (enhanced permeability and retention effect) and active (ligand-receptor binding) targeting mechanisms.

Types of Nanocarriers:
  • Liposomes: Biocompatible vesicles that encapsulate both hydrophilic and hydrophobic drugs; some liposomal formulations like Doxil® are already FDA-approved.
  • Polymeric Nanoparticles: Biodegradable polymers such as PLGA are used to deliver drugs in a controlled-release manner.
  • Dendrimers: Branched macromolecules with precise structures that allow multifunctional drug attachment.
  • Solid Lipid Nanoparticles (SLNs): Offer stability and controlled release, suitable for poorly soluble drugs.
  • Micelles: Amphiphilic molecules forming a core-shell structure, ideal for hydrophobic drug delivery.

Vaccines and immunotherapeutic delivery systems are crucial in preventing and treating infectious diseases, cancers, and autoimmune disorders. These systems are designed to efficiently deliver antigens or immunomodulators to stimulate or modulate the immune response.

1. Vaccine Delivery Systems:
Modern vaccine delivery has evolved from traditional injectable formulations to advanced platforms enhancing stability, efficacy, and targeted immune activation. Common systems include:
  • Lipid-based carriers (e.g., liposomes, lipid nanoparticles): Widely used for mRNA vaccines, offering protection and controlled release.
  • Polymeric nanoparticles: Provide sustained release and targeted delivery.
  • Microneedles and patches: Enable painless, self-administrable, and dermal delivery.
  • Virus-like particles (VLPs): Mimic virus structure without genetic material, inducing strong immunity.
  • Live vectors (e.g., adenoviruses): Used to deliver genetic material for in situ antigen production.
2. Immunotherapeutic Delivery Systems:
These focus on enhancing immune responses against diseases like cancer or dampening autoimmunity:
  • Checkpoint inhibitor carriers: Facilitate localized delivery of antibodies (e.g., anti-PD-1, CTLA-4).
  • Cell-based delivery (e.g., CAR-T cells): Engineered cells target and destroy diseased cells.
  • Exosomes and extracellular vesicles: Natural carriers that can deliver proteins or RNA to specific immune cells.
  • Hydrogels and injectable depots: Provide sustained, localized delivery of cytokines or antigens.
3. Future Directions:
Emerging technologies such as mRNA vaccines, DNA delivery, and bioresponsive smart systems are transforming vaccine and immunotherapy landscapes. Personalization, oral delivery formats, and mucosal immunity stimulation are key areas of ongoing research.

Oral drug delivery remains the most preferred route due to its convenience, patient compliance, and cost-effectiveness. However, it presents several formulation and physiological challenges. Key obstacles include poor solubility and bioavailability of drugs, degradation in the gastrointestinal (GI) tract due to pH variations and enzymatic activity, and first-pass hepatic metabolism, which can significantly reduce therapeutic efficacy.

Innovations in oral drug delivery focus on overcoming these limitations through advanced formulation strategies. Nanotechnology-based carriers (e.g., solid lipid nanoparticles, nanoemulsions), polymer-based systems (e.g., hydrogels, mucoadhesive formulations), and enteric-coated tablets aim to enhance drug stability and absorption. Controlled-release technologies are also being developed to achieve sustained therapeutic levels and reduce dosing frequency.

Injectable and implantable drug delivery devices are advanced systems designed to administer therapeutic agents directly into the body, offering targeted, sustained, and controlled release of drugs.

Injectable Drug Delivery Systems

Injectables deliver drugs through parenteral routes such as intravenous, intramuscular, or subcutaneous injections. These systems are widely used for:
  • Rapid onset of action (e.g., insulin, vaccines)
  • Biologic and peptide therapies, which are often not orally bioavailable
  • Long-acting injectables (LAIs) that provide sustained drug release over days to months (e.g., antipsychotics, contraceptives)

Interactive workshops on formulation techniques serve as dynamic platforms for participants to gain hands-on experience and practical insights into modern drug formulation methods. These workshops typically cover a broad range of formulation strategies, including conventional dosage forms (tablets, capsules, suspensions) and advanced delivery systems (liposomes, nanoparticles, sustained-release systems).
Participants engage in real-time demonstrations, case studies, and group-based problem-solving activities guided by industry experts and academic professionals. Key focus areas often include excipient selection, process optimization, stability testing, scale-up strategies, and regulatory considerations.

Copyright © 2022 MeetingsEra All Rights Reserved.